
- Oncology NEWS International Vol 12 No 1
- Volume 12
- Issue 1
First NCI Health Disparity Grants
BETHESDA, Maryland-Two medical facilities have received the first grants awarded by the National Cancer Institute’s Cooperative Planning Grant for Cancer Disparities Research Partnerships (CDRP). The 5-year, $27 million program provides support for radiation oncology clinical research at institutions that have not traditionally participated in NCI-sponsored studies. The two grants, totaling more than $2.5 million, went to the Rapid City Regional Hospital in South Dakota ($1,404,486), which serves a largely Native American population, and the Mercy Health Center, Laredo, Texas ($1,120,013), which serves a largely Hispanic community.
BETHESDA, MarylandTwo medical facilities have received the first grants awarded by the National Cancer Institute’s Cooperative Planning Grant for Cancer Disparities Research Partnerships (CDRP). The 5-year, $27 million program provides support for radiation oncology clinical research at institutions that have not traditionally participated in NCI-sponsored studies. The two grants, totaling more than $2.5 million, went to the Rapid City Regional Hospital in South Dakota ($1,404,486), which serves a largely Native American population, and the Mercy Health Center, Laredo, Texas ($1,120,013), which serves a largely Hispanic community.
Articles in this issue
almost 23 years ago
Phase II Trial of Phenoxodiol in Recurrent Ovarian Cancer Is launchedalmost 23 years ago
FDA Approves New Taxotere Indication as First-Line Therapy for NSCLCalmost 23 years ago
Most Cancer Pain Is Experienced at the Patient’s Homealmost 23 years ago
HHS Unites Its HIV Advisorsalmost 23 years ago
Pain Therapy Improves Quality of Life for Caregiversalmost 23 years ago
Inex to Seek FDA Approval for Onco TCS (Liposomal Vincristine)almost 23 years ago
CD40L-Expressing Dendritic Cells Eliminate Breast Tumors in Micealmost 23 years ago
Safe Handling Tips for Use of Testosterone Gelalmost 23 years ago
Lumpectomy/Mastectomy Equivalent in Early Breast Canceralmost 23 years ago
New Agent Tested in Refractory and Relapsed Ovarian CancerNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.